Skip to content
10-Q

Quarterly Report

INTEGRATED BIOPHARMA INC INBP

0001437749-25-003744

← back to feed
Filed
Feb 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Feb 13, 2025 30.3M sh
Cash And Equivalents Q2 2025 · Dec 31, 2024 $2.46M
Cash And Equivalents Q2 2025 · Jun 30, 2024 $1.68M
Current Liabilities Q2 2025 · Dec 31, 2024 $5.58M
Current Liabilities Q2 2025 · Jun 30, 2024 $6.12M
Total Liabilities Q2 2025 · Dec 31, 2024 $5.93M
Total Liabilities Q2 2025 · Jun 30, 2024 $6.97M
Current Assets Q2 2025 · Dec 31, 2024 $18.15M
Current Assets Q2 2025 · Jun 30, 2024 $17.88M
Total Assets Q2 2025 · Dec 31, 2024 $25.66M
Total Assets Q2 2025 · Jun 30, 2024 $26.21M
Shares Diluted Q2 2025 · Dec 31, 2023 30.1M sh
Shares Diluted Q2 2025 · Dec 31, 2023 30.03M sh
Capex Q2 2025 · Dec 31, 2023 $62K
Operating Cash Flow Q2 2025 · Dec 31, 2023 −$514K
Stockholders Equity Q2 2025 · Dec 31, 2023 $18.57M
Stockholders Equity Q2 2025 · Sep 30, 2023 $18.89M
Stockholders Equity Q2 2025 · Jun 30, 2023 $18.86M
Eps Diluted Q2 2025 · Dec 31, 2023 −$0.01
Eps Diluted Q2 2025 · Dec 31, 2023 −$0.02
Eps Basic Q2 2025 · Dec 31, 2023 −$0.01
Eps Basic Q2 2025 · Dec 31, 2023 −$0.02
Sga Expense Q2 2025 · Dec 31, 2023 $972K
Sga Expense Q2 2025 · Dec 31, 2023 $1.86M
Net Income Q2 2025 · Dec 31, 2023 −$382K
Net Income Q2 2025 · Dec 31, 2023 −$441K
Net Income Q2 2025 · Sep 30, 2023 −$59K
Operating Income Q2 2025 · Dec 31, 2023 −$452K
Operating Income Q2 2025 · Dec 31, 2023 −$506K
Gross Profit Q2 2025 · Dec 31, 2023 $520K
Gross Profit Q2 2025 · Dec 31, 2023 $1.35M
Cost Of Revenue Q2 2025 · Dec 31, 2023 $10.99M
Cost Of Revenue Q2 2025 · Dec 31, 2023 $23.07M